Show simple item record

dc.contributor.authorMorosini, Pieroes_ES
dc.date.accessioned2017-09-25T21:56:41Z
dc.date.available2017-09-25T21:56:41Z
dc.date.issued2011es_ES
dc.identifier.urihttp://revistas.pucp.edu.pe/index.php/strategia/article/view/4140/4108es_ES
dc.formatapplication/pdf
dc.language.isospa
dc.publisherPontificia Universidad Católica del Perúes_ES
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0*
dc.sourceStrategia; Núm. 21(2011)es_ES
dc.subjectIndustriaes_ES
dc.subjectMedicinaes_ES
dc.subjectIndustria farmacéuticaes_ES
dc.subjectMedicamentoses_ES
dc.subjectOncologíaes_ES
dc.titleEl escándalo de las medicinas oncológicases_ES
dc.typeinfo:eu-repo/semantics/article
dc.type.otherArtículo
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#5.02.04
dc.publisher.countryPE


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International